Categories Earnings, Finance, LATEST

JPMorgan reports solid results for Q2 2018; beats analyst expectations

JPMorgan Chase & Co. (JPM) reported revenues of $27.8 billion for the second quarter of 2018, in line with analyst expectations, and above the prior-year period results. Net income grew 18% to $8.3 billion while diluted EPS came in at $2.29, beating analyst expectations.

Net interest income rose 9% during the quarter driven by higher rates and loan growth while non-interest revenue grew 4% driven by higher markets revenue, investment banking fees and auto lease income. Non-interest expense increased 8%.

JPMorgan second quarter 2018 results
JPMorgan Q2 2018 Earnings Infographic

Average core loans, excluding CIB, were up 7% year-over-year. The company distributed $6.6 billion to shareholders during the second quarter. Last month, JPMorgan received approval to increase its dividend to $0.80 per share from the third quarter of 2018. The company also authorized an equity repurchase program valued at $20.7 billion.

Total revenues in its CCB business increased 10% during the quarter. In the CIB business, revenues grew 11%. Commercial Banking (CB) revenues rose 11%, driven by higher net interest income and higher investment banking revenue.  The AWM segment revenues improved 4%.

In the CCB segment, average loans were up 2%, and average deposits were up 5%. In the CB segment, average loan balances grew 4% while average client deposits were down 1% year-over-year. In the AWM business, average loan balances increased 12% while average deposit balances dropped 7%.

Related: JPMorgan Q2 Earnings Preview: Banking stocks might see green

Related: JPMorgan Q2 2018 Earnings Transcript

Related: JPMorgan Q1 2018 Earnings Infographic

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top